Copyright
©The Author(s) 2021.
World J Virol. Mar 25, 2021; 10(2): 62-68
Published online Mar 25, 2021. doi: 10.5501/wjv.v10.i2.62
Published online Mar 25, 2021. doi: 10.5501/wjv.v10.i2.62
Table 3 Comparison of the novel coronavirus disease 2019 vaccines in clinical trials
| Vaccine | Clinical trials |
| Pfizer vaccine (Name: BNT 162b2) | |
| Type: mRNA | |
| Age: ≥ 16 years old | |
| Dose: 30 μg (0.3 mL) twice (21 d interval) | |
| Efficiency (95%CI): 95.0% (90.3-97.6) | |
| Moderna vaccine (Name: mRNA-1273) | |
| Type: mRNA | |
| Age: ≥ 18 years old | |
| Dose: 100 μg (0.5 mL) twice (28 d interval) | |
| Efficiency (95%CI): 94.5% (86.5-97.8) | |
| AstraZeneca vaccine (Name: ChAdOx1) | |
| Type: Virus vector | |
| Age: ≥ 18 years old | |
| Dose: Low doss: 2.2 × 1010 virus particle andStandard dose: 5 × 1010 virus particle, twice (28 d interval) | |
| Efficiency (95%CI): 90.0% (67.4-97.0) |
- Citation: Seki M. Trends in the management of infectious disease under SARS-CoV-2 era: From pathophysiological comparison of COVID-19 and influenza. World J Virol 2021; 10(2): 62-68
- URL: https://www.wjgnet.com/2220-3249/full/v10/i2/62.htm
- DOI: https://dx.doi.org/10.5501/wjv.v10.i2.62